Thu, Mar 5, 2015, 10:12 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Titan Pharmaceuticals Inc. Message Board

  • settoplunge settoplunge Mar 19, 2013 9:23 AM Flag

    From the Briefing Document:

    "buprenorphine sublingual products have been
    increasingly identified in the illicit drug market, and it is known that they are diverted,
    abused, and misused. Additionally, they have been implicated in an increasing number of
    cases of accidental poisonings of young children. Therefore, a depot injection or an
    implantable product which would be difficult to divert or abuse, and would be less likely
    to be accidentally ingested by young children, offers potential advantages. In addition,
    patients could not periodically discontinue use in order to allow the blocking effect to
    dissipate, so that they could experience the effects of their opioids of choice. Probuphine
    was developed to address these issues."

    "The Division agreed with
    the Applicant that Probuphine had the potential to meet an important public health need
    because implants would be more difficult to divert, and because young children are less
    likely to be accidentally exposed to an implanted rod than to sublingual formulations.
    This application has been accorded Priority Review status in recognition of this potential."

    "In general, the common adverse events associated with Probuphine treatment were
    similar to those seen with sublingual buprenorphine treatment. The hepatic effects and
    effects on cardiac conduction were also consistent with buprenorphine’s expected effects.
    The most notable adverse events for Probuphine were related to the implants themselves
    and to the surgical procedures related to insertion and removal.
    In a safety database comprising 262 patients treated with Probuphine, 6 (2%) experienced
    expulsions or extrusions of implants. Five patients discontinued treatment due to implantsite
    adverse events. No patients treated with placebo implants experienced expulsions,
    extrusions, or AEs leading to discontinuation, suggesting that the irritancy of
    buprenorphine could play a role in these implant site adverse events. More minor
    implant-site AEs were reported in a significant number of study partic

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "In general, the common adverse events associated with Probuphine treatment were
      similar to those seen with sublingual buprenorphine treatment."

      Booooooo! Did that scare you?

    • It looks like APPROVAL to me.

    • Areas of concern:
      "Ultimately, it is necessary to weigh the benefits against the risks, either known or not-yetcharacterized.
      Does Probuphine work well enough to outweigh these concerns?
       Probuphine-treated patients were more likely than patients treated with
      placebo to complete the study and were less likely to require the frequency of
      sublingual buprenorphine administration that met criteria for “treatment
      failure.”
       However, only 32% of Probuphine-treated patients in Study PRO-805
      and 27% in Study PRO-806 submitted opioid-negative samples for
      even half of the urine tests.
       On the other hand, 23% of the Probuphine-treated treated patients in
      Study PRO-805 and 27% in Study PRO-806 had 5% opioid-negative
      samples or fewer.
       Even after for allowing for four months of “grace period,” only 29% of
      Probuphine-treated patients in Study PRO-805 and 23% in Study
      PRO-806 submitted opioid-negative samples for even half of the urine
      tests during the last two months of treatment. Applying a stricter
      definition of 75% opioid-negative samples after four months of
      “grace,” 14% in PRO-805 and 16% in PRO-806 would be considered
      responders.
       The dose of buprenorphine delivered by 4 Probuphine implants is less than a
      third of the dose delivered by 16 mg sublingual buprenorphine. It is possible
      that the dose is sufficient to provide some agonist effects but not to block the
      effects of exogenous opioids. Potentially, Probuphine could deliver just
      enough buprenorphine to allow patients to continue to use illicit opioids
      without experiencing withdrawal when they stop. Patients who do not
      considerably modify their drug-taking behavior may not accrue significant
      benefit from Probuphine treatment."

 
TTNP.OB
0.4630.000(0.00%)Oct 30 2:14 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST